Search the Newsreel

Dawnrays Pharmaceutical Sets Board Meeting to Approve Interim Results and Mull Dividend

Shenzhen Hepalink Sets Board Meeting to Review Interim Results and Dividend

Eyepoint Pharmaceuticals, Inc. $EYPT Stock Position Boosted by California State Teachers Retirement System

The California State Teachers Retirement System significantly increased its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 2,158.3% in the first quarter, now holding 105,101 shares. Several other institutional investors also adjusted their positions in the company. Despite missing earnings per share estimates, Eyepoint Pharmaceuticals exceeded …

Lincoln Pharma Q1 Results FY27: PAT Rs 36 Cr, Revenue Rs 177 crore

Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test

Alnylam Pharmaceuticals (ALNY) recently cut its full-year 2026 TTR product sales guidance by $200 million and is under a securities law investigation, leading to significant share price pressure. Despite a "most popular narrative" suggesting the stock is 47.8% undervalued with a fair value of …

The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call

ANI Pharmaceuticals reported strong Q2 year-on-year growth in its rare disease and generics businesses, exceeding analyst estimates for revenue, EPS, and EBITDA, though the market reacted negatively. CEO Nikhil Lalwani highlighted significant momentum in demand for Cortrophin Gel. Analysts focused on the gout expansion, …

How Investors Are Reacting To Rhythm Pharmaceuticals (RYTM) UK Orphan Expansion For IMCIVREE In Hypothalamic Obesity

Rhythm Pharmaceuticals received expanded UK MHRA authorization and orphan drug designation for IMCIVREE to treat hypothalamic obesity, broadening its market in the UK. While this strengthens the rare-disease thesis for the drug, the company continues to operate at a significant loss, underscoring ongoing funding …

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Lantern Pharma announced its second-quarter 2026 financial results and provided a business update, highlighted by the establishment of Open Medicine AI (OMAI) as a separate company with commercial licensing agreements. The company also reported deepening progression-free survival benefits for LP-300 in EGFR Exon 21 …

It's crunch time for Karyopharm as company faces potential default next month

Karyopharm Therapeutics is facing a potential default next month due to depleted cash reserves and an upcoming debt payment. The company reported a significant loss in Q2 and has limited liquidity, but is negotiating with lenders and exploring financing and strategic alternatives. Karyopharm is …

Lantern Pharma (LTRN) Earnings Date and Reports 2026 $LTRN

Pharming Group N.V.: Fundamentele analyse en financiële beoordelingen | PHARM | NL0010391025

Mirum Pharmaceuticals, Inc. Share Price Live Today – NASDAQ:MIRM Stock Price, Chart, News, History

Cyclopharm (ASX:CYC) Records Revenue Growth While US Technegas Rollout Progresses

Little Green Pharma (ASX:LGP)Hits Record Revenue as Europe Overtakes the Home Market

XERS|Xeris Biopharma Holdings Inc|Price:8.322|Chg%:-0.168

This page provides an overview of Xeris Biopharma Holdings Inc (XERS), including its live stock price, key financial figures, technical analysis, and analyst ratings. The company, which specializes in developing and commercializing products for various therapies like Cushing's syndrome and severe hypoglycemia, currently holds …

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has received a consensus "Buy" rating from seventeen brokerages, with an average 12-month price target of $77.13. The company's stock is currently trading below its recent high, with institutional investors holding a significant 95.45% stake. Recent insider selling has also …

Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share

Zentalis Pharmaceuticals (ZNTL [https://seekingalpha.com/symbol/ZNTL]) announced the pricing of an underwritten public offering [https://seekingalpha.com/pr/20619418-zentalis-pharmaceuticals-announces-pricing-of-underwritten-public-offering] of 23M shares of its common stock at a public offering price of $3.50 per share. Gross proceeds from the offering are expected to be approximately $80.5M before deducting underwriting discounts, …

Zentalis Pharma Prices $80.5 Mln Offering Of Shares At $3.50 Per Share; Stock Down

(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage oncology company, priced a public offering of 23 million shares at $3.50 per share. The total gross proceeds from the offering are expected to be $80.5 million, and the company plans to use the net proceeds …

Ajanta Pharma Ltd. Share Price Today Hits One-Year High

Eton Pharmaceuticals forecasts 2026 revenue to exceed $145M while targeting adjusted EBITDA margin above 35%

Earnings Call Insights: Eton Pharmaceuticals (ETON) Q2 2026 MANAGEMENT VIEW * CEO Sean Brynjelsen said the company delivered “record revenue, significant margin expansion and important progress across both our commercial portfolio and pipeline,” while also completing “several strategic transactions” intended to support long-term growth. …

EyePoint (EYPT) Is Up 5.1% After Steep Q2 Revenue Drop And ESOP-Linked Share Offering Filing

Mankind Pharma shares gain 2% in today's session

Ajanta Pharma Shares Rise 2.17%

Karyopharm Q2 Net Loss Expands; Reaffirms 2026 Revenue Guidance; Plans SNDA For Selinexor In August

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI), a commercial-stage pharmaceutical company, reported financial results for the second quarter of 2026, reflecting a wider net loss and provided an update on the company's myelofibrosis program. In addition, the company reaffirmed the full-year 2026 revenue guidance. Karyopharm, …

Gland Pharma appoints Dr. Reddy’s Lab's Deepak Sapra as CEO; stock hits 52-week high

Why Does Little Green Pharma (ASX:LGP) Shape Quality?

Karyopharm Therapeutics Inc (KPTI) Earnings, Actual EPS, EPS Estimates & Results

Eton Pharmaceuticals Q2 2026 Earnings Call Transcript

ANI Pharmaceuticals (ANIP) Insider Sell: SR. VP, GENERAL COUNSEL & SEC. Meredith Cook Sells 500 Shares

Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals (ANIP), sold 500 shares of the company stock for approximately $37,740. This transaction is part of a broader trend of insider selling at ANI Pharmaceuticals, with 48 insider sells and zero buys over …

Pharming announces commercial launch of Joenja (leniolisib)

Pharming Group N.V. has commercially launched Joenja (leniolisib) in Japan for adult and pediatric patients aged 4 and older with Activated PI3K Delta Syndrome (APDS). This makes Japan the first market where Joenja is available for children aged 4 to 11. OrphanPacific, Inc. is …

Argent BioPharma (ASX:RGT): CannEpil Licence Expansion Adds Veterinary Royalty Opportunity

Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) has announced the pricing of an underwritten public offering of 23 million shares of common stock at $3.50 per share, aiming to raise approximately $80.5 million in gross proceeds. The offering is expected to close on August 17, 2026, with …

ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares under 10b5-1 plan

Meredith Cook, Senior Vice President, General Counsel and Secretary at ANI Pharmaceuticals (ANIP), sold 500 shares of common stock at $75.48 per share on August 13, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted in September 2025. Following the sale, …

What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders

Cue Biopharma, Inc. SEC Filing (Aug 14, 2026)

This article reports on a Form 144 SEC filing by Cue Biopharma, Inc. (CUE) on August 14, 2026. The filing indicates a proposed sale of 8,829 shares of common stock with an aggregate market value of $266,106.06, acquired through Restricted Stock Units vesting under …

X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026)

This article reports on an SEC Form 144 filing by X4 Pharmaceuticals, Inc. (XFOR) on August 13, 2026. The filing indicates a proposed sale of 24,576 shares of common stock with an aggregate market value of $111,943.68, acquired through restricted stock unit vesting. The …